Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Etienne

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Emerging Infectious Diseases|July 19, 2005
Veillonella montpellierensis endocarditisClarisse Rovery, Anne Etienne, Cédric Foucault, et al.
American Journal of Hematology|April 1, 2004
Severe hemolytic anemia due to cold agglutinin complicating untreated chronic hepatitis C: efficacy and safety of anti-CD20 (rituximab) treatmentAnne Etienne, Stéphane Gayet, Florian Vidal, et al.
Cancer|October 20, 2010
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative studyThomas Prebet, Anne Etienne, Raynier Devillier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 3, 2012
Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blastsJulie Gertner-Dardenne, Remy Castellano, Emilie Mamessier, et al.
Cancer|February 28, 2007
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemiaAnne Etienne, Benjamin Esterni, Aude Charbonnier, et al.
Leukemia & Lymphoma|May 16, 2012
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline inductionThomas Prébet, Estelle Jean, Aurélie Autret, et al.
Blood|September 25, 2012
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remissionNorbert Vey, Jean-Henri Bourhis, Nicolas Boissel, et al.
Leukemia & Lymphoma|October 23, 2012
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemiaRaynier Devillier, Roberto Crocchiolo, Anne Etienne, et al.
Haematologica|October 8, 2008
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaJean-Valère Malfuson, Anne Etienne, Pascal Turlure, et al.
Cancer Genetics and Cytogenetics|June 19, 2007
Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genesAnne Etienne, Nadine Carbuccia, José Adélaïde, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Emerging Infectious Diseases|July 19, 2005
Veillonella montpellierensis endocarditisClarisse Rovery, Anne Etienne, Cédric Foucault, et al.
American Journal of Hematology|April 1, 2004
Severe hemolytic anemia due to cold agglutinin complicating untreated chronic hepatitis C: efficacy and safety of anti-CD20 (rituximab) treatmentAnne Etienne, Stéphane Gayet, Florian Vidal, et al.
Cancer|October 20, 2010
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative studyThomas Prebet, Anne Etienne, Raynier Devillier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 3, 2012
Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blastsJulie Gertner-Dardenne, Remy Castellano, Emilie Mamessier, et al.
Cancer|February 28, 2007
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemiaAnne Etienne, Benjamin Esterni, Aude Charbonnier, et al.
Leukemia & Lymphoma|May 16, 2012
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline inductionThomas Prébet, Estelle Jean, Aurélie Autret, et al.
Blood|September 25, 2012
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remissionNorbert Vey, Jean-Henri Bourhis, Nicolas Boissel, et al.
Leukemia & Lymphoma|October 23, 2012
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemiaRaynier Devillier, Roberto Crocchiolo, Anne Etienne, et al.
Haematologica|October 8, 2008
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaJean-Valère Malfuson, Anne Etienne, Pascal Turlure, et al.
Cancer Genetics and Cytogenetics|June 19, 2007
Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genesAnne Etienne, Nadine Carbuccia, José Adélaïde, et al.
Pageof 2